Yugal Sikri
#850Managing Director
67
Age
42y
Exp
10y
Tenure
7/10
Risk
🎓 B.Tech, B.Sc · IIT BHU (Indian Institute of Technology, Banaras Hindu University) and Delhi University (M.Pharm/B.Pharm); also JBIMS Mumbai (MBA)
🏛️ IIT+India-Elite
CompensationTBP
Personality
7
Open
6
Cons
6
Extr
6
Agre
4
Neur
RPG LifeScience.
Healthcare · Small Cap
High Growth · Performance-Driven
About
Yugal Sikri is the Managing Director of RPG LifeScience., a Small Cap company in the Healthcare sector with a market cap of ₹3K Cr. A Transformational leader with 42 years of experience, he is known for intuition-driven decision-making and organic builder strategy. Publicly emphasized aggressive portfolio restructuring and focus on high-growth therapeutic areas to revitalize the company's market position.
FAQ
What is Yugal Sikri's leadership style?
Yugal Sikri is classified as a Transformational leader. He is intuition-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Yugal Sikri's educational background?
Yugal Sikri holds a B.Tech, B.Sc from IIT BHU (Indian Institute of Technology, Banaras Hindu University) and Delhi University (M.Pharm/B.Pharm); also JBIMS Mumbai (MBA).
Who is the CEO of RPG LifeScience.?
Yugal Sikri is the Managing Director of RPG LifeScience.. He has been with the company for 10 years and in the current role for 8 years.
Leadership DNA
ArchetypeTransformational
MotivationCategory Creator
CrisisRestructurer
DecisionIntuition-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerSteady Employer
BrandTechnical-Expert
FocusProduct Innovation
OrientationSector Adjacent
Leadership Evidence
“Publicly emphasized aggressive portfolio restructuring and focus on high-growth therapeutic areas to revitalize the company's market position.”
⚡ Crisis●●●●○
Sikri spearheaded a strategic turnaround at RPG Life Sciences by rationalizing the product portfolio and exiting non-core segments to focus on specialty and generic niches.
🎯 Motivation●●●○○
His leadership has been defined by shifting the company's focus toward high-value specialty products and innovative drug delivery systems rather than just volume generics.
👥 People●●●○○
His transformational approach is characterized by rigorous operational discipline and a data-centric focus on improving EBITDA margins and asset turnover.
📈 Growth●●●●○
He has focused on driving growth through internal product innovation, portfolio optimization, and operational efficiency improvements rather than large-scale M&A.
💡 Innovation●●●●○
The company focuses on high-quality niche generics and branded formulations, leveraging established therapeutic categories rather than pioneering new molecular entities.
🏃 Pace●●●●○
The company has demonstrated a consistent, methodical turnaround and growth strategy focused on operational efficiency and portfolio optimization over several years.
🌱 Purpose●●●○○
The company emphasizes 'caring for life' through its focus on chronic therapies and adherence to ESG reporting standards in its annual disclosures.
🏷️ Brand●●●●○
The firm is recognized for its specialized capabilities in complex therapeutic segments like nephrology, oncology, and immunology.
🤝 Customer●●●●○
The company primarily operates through a B2B model, supplying pharmaceutical products to hospitals, medical practitioners, and distributors rather than direct-to-consumer retail.
💼 Employer●●●○○
As part of the RPG Group, the company maintains a reputation for stable, professional corporate governance and long-term career development within the mid-market pharma space.
📋 Mandate
To scale in the competitive Indian pharma market, the company needs a leader who can prioritize portfolio expansion and R&D-led growth.
🏢 Culture●●●●○
Professional management under an experienced CEO focusing on high-growth pharma segments necessitates a clear, output-oriented KPI structure.
Financials
Revenue FY25₹648 Cr
PAT FY25₹183 Cr
Rev CAGR 5Y14%
OPM21.7%
NPM28.3%
ROE34.5%
ROCE26.1%
P/E15.4
Fwd P/E65.8
P/B5.6
D/E—
Promoter74.9%
Institutional7.5%
Mkt Cap₹3K Cr
Compensation
To Be Published
Data being verified from audited reports
